Pediatric kidney transplantation

• Verfasst von: Opelz, Gerhard [VerfasserIn]
• Verfasst von: Döhler, Bernd [VerfasserIn]
• Titel: Pediatric kidney transplantation
• Titelzusatz: analysis of donor age, HLA match, and posttransplant non-Hodgkin lymphoma: a collaborative transplant study report
• Verf.angabe: Gerhard Opelz and Bernd Döhler
• Jahr: 2010
• Umfang: 6 S.
• Fussnoten: Gesehen am 14.06.2023
• Titel Quelle: Enthalten in: Transplantation
• Ort Quelle: Hagerstown, Md. : Lippincott Williams & Wilkins, 1963
• Jahr Quelle: 2010
• Band/Heft Quelle: 90(2010), 3 vom: 15. Aug., Artikel-ID 292, Seite 1-6
• ISSN Quelle: 1534-6080
• DOI: doi:10.1097/TP.0b013e3181e46a22
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1848977662

Abstract

Background. - The impact and relationship of donor age, human leukocyte antigen (HLA) matching, and posttransplant non-Hodgkin lymphoma in pediatric kidney recipients are not completely understood. - Methods. - We analyzed Collaborative Transplant Study data from 9209 pediatric kidney transplant recipients to examine the effects of donor age and HLA match on graft survival and the relationship between HLA match and occurrence of non-Hodgkin lymphoma. - Results. - Survival rates using donors aged 11 to 17, 18 to 34, or 35 to 49 years were similar. Cox regression analysis showed that two HLA-DR mismatches were associated with lower graft survival in transplants performed during 1988 to 1997 (P<0.001) but not during the 1998 to 2007 period (P=0.95). A hierarchical relationship was observed for the effect of increasing numbers of combined HLA-A+B+DR mismatches on graft survival during the 1988 to 1997 (P<0.001) and the 1998 to 2007 period (P<0.001). An association between two HLA-DR mismatches and non-Hodgkin lymphoma was demonstrated by multivariate analysis (hazard ratio for 2 vs. 0-1 DR mismatches 2.04, P=0.021), and the result was consistent during both 10-year periods. - Conclusion. - We recommend that (1) kidneys from deceased donors up to 49 years be allocated to children, (2) an acceptable HLA-A+B+DR match be attempted in patients with relatively common HLA phenotypes, and (3) transplants with two HLA-DR mismatches be avoided to reduce the risk of posttransplant non-Hodgkin lymphoma.